Syneos Health inks service deal with Pfizer

By Jenni Spinner

- Last updated on GMT

(AnuchaCheechang/iStock via Getty Images Plus)
(AnuchaCheechang/iStock via Getty Images Plus)

Related tags Syneos Health Pfizer Clinical research Drug development

The clinical development and consulting firm has signed a three-year service agreement to support the pharma firm with development service solutions.

Syneos Health, a contract research organization (CRO) and consulting firm, has signed a three-year service agreement with global pharmaceutical firm Pfizer. Under the terms of the agreement, Syneos Health will provide product development solutions to the drug company, with the option to extend for two additional years.

Prior to this newly signed agreement, the two companies had worked together frequently over the years. Syneos has a record of providing insights and advice regarding clinical research and commercial services to support development of various products. According to Syneos, this new agreement will continue that relationship, with the company providing service to Pfizer projects around the globe, covering a variety of therapeutic areas.

Paul Colvin, president of Syneos Health Clinical Solutions, said the pharmaceutical firm stands to benefit from his company’s range of capabilities and knowledge.

“Our ability to deliver deep therapeutic expertise, while bringing forward insights that can facilitate shorter and more efficient trials, has proven to be advantageous in our work with Pfizer​,” he said. “This new agreement allows us to continue our collaboration to deliver flexible and innovative solutions​."

We are pleased to expand our Pfizer relationship to optimize their portfolio and deliver on our shared purpose to change patients’ lives​,” Colvin added.

Earlier this year, Syneos Health senior vice president of real-world and late phase David Thompson spoke on the future of virtual/decentralized technology in clinical research and drug development​.

In March, Pfizer joined Gilead, Merck, Novartis and other pharmaceutical giants on a COVID-19 solution collaboration​, facilitated by the Bill and Melinda Gates Foundation.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more